WHO Drug Information Vol. 24, No. 4, 2010

Proposed INN: List 104 WHO Drug Information, Vol. 24, No. 4, 2010atinumab immunoglobuline G4-kappa, anti-[Homo sapiens RTN4 (réticulon 4,inhibiteur de la croissance des neurites, NOGO), isoforme A], Homosapiens anticorps monoclonal;chaîne lourde gamma4 (1-441) [Homosapiens VH (IGHV3-7*01 (93.80%) -(IGHD)-IGHJ2*01 T122>S)[8.8.7] (1-114) -IGHG4*01 (115-441)], (128-214')-disulfure avec lachaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01 R123>K) [6.3.9] (1'-107') -IGKC*01(108'-214')]; dimère (220-220'':223-223'')-bisdisulfureimmunomodulateuratinumabinmunoglobulina G4-kappa, anti-[RTN4 de Homo sapiens (reticulón4, inhibidor del crecimiento de las neuritas, NOGO), isoforma A],anticuerpo monoclonal de Homo sapiens;cadena pesada gamma4 (1-441) [VH de Homo sapiens (IGHV3-7*01(93.80%) -(IGHD)-IGHJ2*01 T122>S) [8.8.7] (1-114) -IGHG4*01(115-441)], (128-214')-disulfuro con la cadena ligera kappa (1'-214')[Homo sapiens V-KAPPA (IGKV3-11*01 (100.00%) -IGKJ5*01R123>K) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (220-220'':223-223'')-bisdisulfuroinmunomodulador1226761-65-4Heavy chain / Chaîne lourde / Cadena pesadaEVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWMSWVRQA PGKGLEWVAT 50IKQDGSQKNY VDSVKGRFTI SRDNAKNSLY LRLNSLRAED TAVYYCATEL 100FDLWGRGSLV TVSSASTKGP SVFPLAPCSR STSESTAALG CLVKDYFPEP 150VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSSL GTKTYTCNVD 200HKPSNTKVDK RVESKYGPPC PSCPAPEFLG GPSVFLFPPK PKDTLMISRT 250PEVTCVVVDV SQEDPEVQFN WYVDGVEVHN AKTKPREEQF NSTYRVVSVL 300TVLHQDWLNG KEYKCKVSNK GLPSSIEKTI SKAKGQPREP QVYTLPPSQE 350EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400YSRLTVDKSR WQEGNVFSCS VMHEALHNHY TQKSLSLSLG K 441Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKP GQAPRLLIYD 50ASNRATGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCQQ RSNWPITFGQ 100GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200LSSPVTKSFN RGEC 214Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 141-197 255-315 361-41922''-96'' 141''-197'' 255''-315'' 361''-419''Intra-L 23'-88' 134'-194'23'''-88''' 134'''-194'''Inter-H-L 128-214' 128''-214'''Inter-H-H 220-220'' 223-223''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación291, 291''atopaxarumatopaxaratopaxaratopaxar2-(5,6-diethoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl)-1-[3-tert-butyl-4-methoxy-5-(morpholin-4-yl)phenyl]ethan-1-oneplatelet aggregation inhibitor2-(5,6-diéthoxy-7-fluoro-1-imino-1,3-dihydro-2H-isoindol-2-yl)-1-[3-tert-butyl-4-méthoxy-5-(morpholin-4-yl)phényl]éthanoneantiagrégant plaquettaire2-(5,6-dietoxi-7-fluoro-1-imino-1,3-dihidro-2H-isoindol-2-il)-1-[3-terc-butil-4-metoxi-5-(morfolin-4-il)fenil]etan-1-onainhibidor de la agregación plaquetaria358